90 related articles for article (PubMed ID: 15902286)
21. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
22. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression.
Martinez JC; Mateo M; Sánchez-Beato M; Villuendas R; Orradre JL; Algara P; Sánchez-Verde L; García P; López C; Martínez P
J Pathol; 1995 Sep; 177(1):27-34. PubMed ID: 7472776
[TBL] [Abstract][Full Text] [Related]
23. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene.
Lossos IS; Warnke R; Levy R
Leukemia; 2002 Sep; 16(9):1857-62. PubMed ID: 12200704
[TBL] [Abstract][Full Text] [Related]
24. Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death.
Blagosklonny MV
J Natl Cancer Inst; 2001 Feb; 93(3):239-40. PubMed ID: 11158196
[No Abstract] [Full Text] [Related]
25. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
[TBL] [Abstract][Full Text] [Related]
26. Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch.
Mannouji K; Tasaka T; Akiyama T; Irei I; Sano F; Matsuhashi Y; Wada H; Tohyama K; Sugihara T; Sadahira Y
Pathol Int; 2009 Apr; 59(4):261-4. PubMed ID: 19351371
[TBL] [Abstract][Full Text] [Related]
27. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma.
Lee JT; Innes DJ; Williams ME
J Clin Invest; 1989 Nov; 84(5):1454-9. PubMed ID: 2509518
[TBL] [Abstract][Full Text] [Related]
28. Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma.
Ludvigsen M; Madsen C; Kamper P; Hamilton-Dutoit SJ; Bendix K; d'Amore F; Honoré B
Blood Cancer J; 2015 Mar; 5(3):e293. PubMed ID: 25768407
[No Abstract] [Full Text] [Related]
29. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.
Bellido M; Capello D; Altés A; Estivill C; Gaidano G; Pujol R; Bordes R; Baiget M; Saglio G; Sierra J; Nomdedéu JF
Haematologica; 2002 Sep; 87(9):908-17. PubMed ID: 12217802
[TBL] [Abstract][Full Text] [Related]
30. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.
Song L; Zlobin A; Ghoshal P; Zhang Q; Houde C; Weijzen S; Jiang Q; Nacheva E; Yagan D; Davis E; Galiegue-Zouitina S; Catovsky D; Grogan T; Fisher RI; Miele L; Coignet LJ
Cancer Res; 2005 Jun; 65(11):4554-61. PubMed ID: 15930272
[TBL] [Abstract][Full Text] [Related]
31. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
Dubs-Poterszman MC; Tocque B; Wasylyk B
Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
[TBL] [Abstract][Full Text] [Related]
32. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression.
Beverly LJ; Felsher DW; Capobianco AJ
Cancer Res; 2005 Aug; 65(16):7159-68. PubMed ID: 16103066
[TBL] [Abstract][Full Text] [Related]
33. bcl-2 and p53 protein expression in follicular lymphoma.
Cooper K; Haffajee Z
J Pathol; 1997 Jul; 182(3):307-10. PubMed ID: 9349233
[TBL] [Abstract][Full Text] [Related]
34. [Germinoblastoma of the orbit].
Gabel VP
Ber Zusammenkunft Dtsch Ophthalmol Ges; 1972; 71():560-3. PubMed ID: 4582032
[No Abstract] [Full Text] [Related]
35. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting.
D'Orazi G; Marchetti A; Crescenzi M; Coen S; Sacchi A; Soddu S
J Gene Med; 2000; 2(1):11-21. PubMed ID: 10765501
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
37. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
38. The clinical course of follicular lymphoma.
Rohatiner AZ; Lister TA
Best Pract Res Clin Haematol; 2005 Mar; 18(1):1-10. PubMed ID: 15694181
[TBL] [Abstract][Full Text] [Related]
39. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective.
Gaidano G; Pastore C; Volpe G
Haematologica; 1995; 80(5):454-72. PubMed ID: 8566891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
